Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of PF-08634404 plus chemotherapy versus pembrolizumab plus chemotherapy in first-line advanced or metastatic non-small cell lung cancer
MOH_2025-11-26_015496Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- Nov 2025
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of PF-08634404, pembrolizumab, carboplatin, paclitaxel and pemetrexed in non-small cell lung cancer (NSCLC) (4 arms), sponsored by Pfizer. Started Nov 2025; status: recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on MOH_2025-11-26_015496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-11-26_015496.